Lubiprostone.
Sucampo Pharmaceuticals Inc and Takeda Pharmaceutical Co Ltd are developing, a ClC-2 chloride channel activator and a bicyclic member of a series of fatty acid compounds, for the potential treatment of a number of gastrointestinal conditions, including constipation, irritable bowel syndrome, postoperative bowel dysfunction and opioid bowel dysfunction.
Winpenny
John P
JP
University of East Anglia, Biomedicine Group, School of Medicine, Health Policy & Practice, Institute of Health, Norwich, UK. john.winpenny@uea.ac.uk
D000527:Alprostadil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D003248:Constipation / Q000188:drug therapy*; D003967:Diarrhea / Q000139:chemically induced; D005227:Fatty Acids / Q000627:therapeutic use*; D006261:Headache / Q000139:chemically induced; D006801:Humans; D000068238:Lubiprostone; D009325:Nausea / Q000139:chemically induced; D016032:Randomized Controlled Trials as Topic
D005227:Fatty Acids; D000068238:Lubiprostone; D000527:Alprostadil